Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve T. Rodler, Gabriel N. Hortobágyi, Priyanka Sharma et al.|The Lancet Oncology|2023Cited by 103
Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaKsenija Nesic, Clare L. Scott, Olga Kondrashova et al.|Cancer Research|2021Cited by 91
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline <i>BRCA</i>-associated breast cancer (SWOG S1416).Priyanka Sharma, Gabriel N. Hortobágyi, Eve T. Rodler et al.|Journal of Clinical Oncology|2020Cited by 49
Homologous recombination–deficient mutation cluster in tumor suppressor <i>RAD51C</i> identified by comprehensive analysis of cancer variantsRohit Prakash, Kara A. Bernstein, Yashpal Rawal et al.|Proceedings of the National Academy of Sciences|2022Cited by 30
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nešić, Harold C. Sullivan, John J. Krais et al.|Molecular Cancer|2024Cited by 28